Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JB-128
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Small Molecules
01
Overview
JB-128 is a synthetic small molecule analog of the natural product Salinopostin A (Sal A) [7911]. It is being developed as an antimalarial agent targeting the asexual blood stages of *Plasmodium falciparum*, with the schizont stage being particularly sensitive [7911]. JB-128 acts by inhibiting parasite α/β serine hydrolases, including a homolog of monoacylglycerol lipase (MAGL). Resistance to JB-128 is mediated by mutations in the mitochondrial PRELI domain-containing protein (PfPRELI), which is essential for parasite growth [7911]. JB-128 was co-developed through a collaboration involving Stanford University, Columbia University, and Calibr at Scripps Research Institute [7911].
02
Targets
MGLL (Monoacylglycerol lipase)
Beyond the preview
Go deeper on JB-128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JB-128.